Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of FCN-159 in recurrent or progressive low-grade glioma
ChiCTR2300069156Phase 2Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luvometinib in glioma, sponsored by Beijing Tiantan Hospital. Primary endpoint: Objective response rate. Started Dec 2021; status: recruiting.
02
Drugs
luvometinib
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR2300069156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069156.